drugset / Trial / NCT05628870
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy or combination with Dalpiciclib Isethionate Tablets in patients with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).
Timeline
- Start
- 2023-02-07
- Primary completion
- 2025-06
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | — | Oral |
| Subject | HRS-1358 | Unknown | — | Oral |